Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and EssilorLuxottica Unsponsored ADR (ESLOY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emph ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K ENVISTA HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 83-2206728 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) ...

Key Takeaways NVST reported Q4 adjusted EPS of 38 cents, up 58%, with revenues rising 15% and beating estimates.NVST's Specialty Products & Technologies and Equipment & Consumables posted double-digit sales growth.NVST saw gross margin fall 235 bps on higher costs, but operating margin expanded to 9.8%.Envista Holdings Corporation (NVST) reported adjusted earnings per share (EPS) of 38 cents in the fourth quarter of 2025, up 58.3% year over year. The bottom line surpassed the Zacks Consensus Estimate by 18. ...

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the short term [3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [4] Growth Score - The Growth Score assesses a company's financial health and future outlook, analyzing projected earnings, sales, and cash flow to find sustainable growth stocks [5] Momentum Score - The Momentum Score evaluates stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive rating that highlights stocks with attractive value, growth potential, and positive momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock Highlight: Envista Holdings Corporation (NVST) - Envista, a subsidiary of Danaher Corporation, specializes in the dental sector and has integrated over 25 dental businesses [12] - NVST holds a 1 (Strong Buy) Zacks Rank and a VGM Score of A, indicating strong investment potential [12] - The company is projected to achieve year-over-year earnings growth of 17.7% for the current fiscal year, with recent earnings estimates revised upward [13] - With a solid Zacks Rank and favorable Growth and VGM Style Scores, NVST is recommended for investors [14]

Core Viewpoint - Envista (NVST) is positioned as a strong investment opportunity due to its improving earnings outlook and positive analyst sentiment [1][2]. Earnings Estimate Revisions - Analysts are increasingly optimistic about Envista's earnings prospects, leading to a rising trend in estimate revisions, which typically correlates with stock price movements [2]. - The current-quarter earnings estimate is projected at $0.30 per share, reflecting a year-over-year increase of +25.0%, with a recent 11.64% rise in consensus estimates over the last 30 days [5][6]. - For the full year, the earnings estimate is expected to be $1.36 per share, indicating a year-over-year change of +14.3%, with a 7.96% increase in consensus estimates due to five upward revisions [6][7]. Zacks Rank and Performance - Envista has achieved a Zacks Rank 1 (Strong Buy), indicating strong agreement among analysts on upward earnings revisions, which historically leads to significant outperformance [3][8]. - Stocks with a Zacks Rank 1 and 2 have shown to significantly outperform the S&P 500, suggesting a favorable investment environment for Envista [8]. Stock Performance - Envista's stock has increased by 23.2% over the past four weeks, driven by strong estimate revisions, indicating potential for further upside [9].

Core Viewpoint - Envista (NVST) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook for its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which in turn affects stock prices [4]. Business Improvement Indicators - Rising earnings estimates and the Zacks Rank upgrade suggest an improvement in Envista's underlying business, which could lead to increased stock prices as investors respond positively to this trend [5][10]. - Over the past three months, the Zacks Consensus Estimate for Envista has increased by 8.3%, indicating a positive revision in earnings expectations [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions, positioning Envista favorably for potential market-beating returns [9][10].

Core Viewpoint - BofA analyst Allen Lutz has raised the price target for Envista (NVST) to $32 from $28 while maintaining a Buy rating on the shares, indicating a positive outlook for the company following its earnings report [1]. Revenue and EBITDA Estimates - The firm is increasing FY26 revenue and EBITDA estimates due to modestly better organic growth and a favorable foreign exchange tailwind, suggesting improved financial performance for Envista [1].

Core Insights - Envista Holdings Corp. (NYSE:NVST) experienced a significant stock price increase of 23.4% week-on-week, reaching a nearly three-year high, driven by strong earnings performance and a return to profitability [1][3] Financial Performance - The company reported a net income of $47 million for the previous year, a turnaround from a net loss of $1.1 billion in 2024 [3] - Year-on-year sales increased by 8% to $2.7 billion, up from $2.5 billion [3] - In Q4, net profit surged by 2,642% to $32.9 million from $1.2 million in the same quarter the previous year [3] - Q4 sales grew by 15% to $750.6 million, compared to $652.9 million in the same period last year [3] Strategic Focus - The CEO emphasized a disciplined focus on growth, operations, and employee development, highlighting positive growth across all major businesses and geographies [4] - The company returned $166 million to shareholders through share repurchases [4] Future Outlook - For the current year, Envista aims to grow core sales by 2 to 4% and expects adjusted EBITDA to increase by 7 to 13% [5] - Adjusted diluted earnings per share are projected to be between $1.35 and $1.45 [5]

Core Insights - Envista reported broad-based growth in Q4 2025, with core sales increasing by 10.8% and full-year sales reaching $2.7 billion, reflecting a 6.5% increase year-over-year [4][6][5] - The company emphasized its Value Creation Plan, focusing on growth, operations, and people, with medium-term financial objectives of 2%-4% core growth, 4%-7% EBITDA growth, and 7%-10% EPS growth [3][4] - Management highlighted significant cost reductions, with G&A spending down by over $35 million in 2025, and a $250 million share repurchase program initiated [1][4] Financial Performance - Full-year adjusted EBITDA margin improved to 13.7%, a 190 basis point increase from 2024, while adjusted EPS rose to $1.19, up $0.46 year-over-year [14] - Free cash flow for 2025 was reported at $231 million, with a conversion rate of 114% [14] - Q4 sales were reported at $751 million, with foreign exchange contributing nearly 400 basis points to growth [8][10] Growth Drivers - All business segments delivered positive growth, with notable contributions from new product introductions and increased clinical training, resulting in nearly $100 million in revenue from products launched in the last year [2][4] - The company trained 30% more customers in 2025, which contributed to accelerating growth [2] - New product launches included major introductions in Spark and diagnostics, with plans for further launches in 2026 [7][4] Market Outlook - For 2026, Envista guided core sales growth of 2%-4%, adjusted EBITDA growth of 7%-13%, and adjusted EPS between $1.35 and $1.45 [18] - Management expects the dental market to remain stable with potential for modest improvement, while also noting calendar effects that may impact quarterly growth [19] - The company anticipates a $30 million headwind from tariffs in 2026, with strategies in place to offset this through pricing and cost reductions [20] Segment Performance - Specialty Products & Technologies saw revenue growth of nearly 16% year-over-year, with core sales up 10.9% [16] - Equipment and Consumables reported core sales growth of 10.7%, with diagnostics achieving double-digit growth globally [17] - Adjusted operating margins in Specialty Products & Technologies improved significantly, while Equipment and Consumables faced margin declines due to investments for future growth [16][17]

Core Insights - Envista (NVST) reported revenue of $750.6 million for Q4 2025, marking a 15% year-over-year increase and exceeding the Zacks Consensus Estimate by 11.16% [1] - The company's EPS for the quarter was $0.38, up from $0.24 a year ago, representing an EPS surprise of 18.23% over the consensus estimate of $0.32 [1] Financial Performance - Revenue from Equipment & Consumables was $274.7 million, surpassing the average estimate of $248.55 million by analysts, reflecting a year-over-year increase of 13.5% [4] - Revenue from Specialty Products & Technologies reached $475.9 million, exceeding the average estimate of $429.04 million, with a year-over-year change of 15.8% [4] - Adjusted Operating Profit for Equipment & Consumables was reported at $55.2 million, compared to the average estimate of $52.56 million [4] - Adjusted Operating Profit for Specialty Products & Technologies was $77 million, exceeding the average estimate of $59.59 million [4] Market Performance - Envista's shares have returned +3.2% over the past month, outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]